2-羟基-2-(4-甲基-1,3-噻唑-2-基)丙酸乙酯 | 29510-47-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-羟基-2-(4-甲基-1,3-噻唑-2-基)丙酸乙酯
• 英文名称: ethyl 2-hydroxy-2-(4-methylthiazol-2-yl)propanoate
• 英文别名: Ethyl 2-hydroxy-2-(4-methyl-1,3-thiazol-2-yl)propanoate
• CAS: 29510-47-2
• 化学式: C₉H₁₃NO₃S
• 分子量: 215.273
• InChiKey: FEDXUUDVYOISSJ-UHFFFAOYSA-N

物化性质

• 沸点：
  317.2±37.0 °C(Predicted)
• 密度：
  1.247±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  87.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-羟基-2-(4-甲基-1,3-噻唑-2-基)丙酸乙酯 在 一水合肼 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 N-(3-bromo-4-fluorophenyl)-2-(2-hydroxy-2-(4-methylthiazol-2-yl)propanoyl)hydrazine-1-carbothioamide
  参考文献：
  名称：

  Design, Synthesis, and Evaluation of New Thiadiazole-Based Direct Inhibitors of Enoyl Acyl Carrier Protein Reductase (InhA) for the Treatment of Tuberculosis

  摘要：

  Mycobacterial enoyl acyl carrier protein reductase (InhA) is a clinically validated target for the treatment of tuberculosis infections, a disease that still causes the death of at least a million people annually. A known class of potent, direct, and competitive InhA inhibitors based on a tetracyclic thiadiazole structure has been shown to have in vivo activity in murine models of tuberculosis infection. On the basis of this template, we have here explored the medicinal chemistry of truncated analogues that have only three aromatic rings. In particular, compounds 8b, 8d, 8f, 8l, and 8n show interesting features, including low nanomolar InhA IC50, submicromolar antimycobacterial potency, and improved physicochemical profiles in comparison with the tetracyclic analogues. From this series, 8d is identified as having the best balance of potency and properties, whereby the resolved 8d S-enatiomer shows encouraging in vivo efficacy.

  DOI：

  10.1021/jm501029r
• 作为产物：
  描述：

  ethyl 2-(4-methyl-1,3-thiazol-2-yl)propanoate 在 盐酸 、 水 、 silver(l) oxide 作用下， 以 水 、 甲苯 、 乙腈 为溶剂， 反应 3.17h， 生成 2-羟基-2-(4-甲基-1,3-噻唑-2-基)丙酸乙酯
  参考文献：
  名称：

  [EN] 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS
  [FR] DÉRIVÉS DE 3-AMINO-PYRAZOLE UTILES CONTRE LA TUBERCULOSE

  摘要：

  化合物的化学式（I）或其药学上可接受的盐：（I），其中：Het是一个5到10个成员的杂芳环；X是N且Y是CR5；或X是C且Y是S；Z从N和CH中选择；R1从H和C1-2烷基中选择；R2从H，C1-2烷基，OH，-CH2OH和C1-2烷氧基中选择；每个R3独立地从OH，C1-3烷基，F，Cl，Br，NH2和C1-3烷氧基中选择；R4从C1-3烷基和卤代C1-3烷基中选择；R5从H，C1-3烷基和卤代C1-3烷基中选择；R6和R7要么i）各自独立地从H，C1-3烷基和C1-3烷氧基中选择；要么ii）R6和R7与它们附着的环一起形成一个9个成员的双环环；p为0-3；RA从H和C1-3烷基中选择，提供了含有它们的组合物，它们在治疗中的用途，例如在结核病治疗中的用途，以及这类化合物的制备方法。

  公开号：

  WO2012049161A1

文献信息

• (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS
  申请人：Ballell Pages Lluis

  公开号：US20120095064A1

  公开（公告）日：2012-04-19

  A compound of Formula (I) wherein: either X is N and Y is CR 5 or X is C and Y is S; Z is selected from N and CH; R 1 is selected from H and Me; R 2 is selected from H, OH, OMe and Me; each R 3 is independently selected from C 1-3 alkyl, F, Cl, Br, CF 3 and NH 2 ; R 4 is selected from Me, CF 3 , NO 2 and CHF 2 ; R 5 is selected from H, Me and CHF 2 ; R 6 is selected from H and Me; and p is 0-3, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

  一个由Formula (I)组成的化合物 其中：X为N且Y为CR5，或者X为C且Y为S；Z从N和CH中选择；R1从H和Me中选择；R2从H、OH、OMe和Me中选择；每个R3独立地从C1-3烷基、F、Cl、Br、CF3和NH2中选择；R4从Me、 、NO2和CHF2中选择；R5从H、Me和 中选择；R6从H和Me中选择；p为0-3，提供了含有它们的组合物，它们在治疗中的使用，例如在结核病治疗中的使用，以及制备这类化合物的方法。
• Mechanisms of thiamine-catalyzed reactions. Decarboxylation of 2-(1-carboxy-l-hydroxyethyl)-3,4-dimethylthiazolium chloride
  作者：John Crosby、Richard Stone、Gustav E. Lienhard

  DOI：10.1021/ja00712a048

  日期：1970.5

  Previous investigations have indicated that the thiamine pyrophosphate-dependent enzymatic decarboxylation of pyruvate to acetaldehyde proceeds via the decarboxylation of 2-(l-carboxy-l-hydroxyethyl)thiamine pyrophosphate (Ia) to 2-(l-hydroxyethyl)thiamine pyrophosphate (IIa). This paper reports the synthesis of an analog of Ia, 2-(l-carboxy-l-hydroxyethyl)-3,4-dimethylthiazolium chloride (CHDT chloride)

  先前的研究表明，丙酮酸硫胺素依赖的酶促脱羧反应生成乙醛是通过 2-(l-羧基-l-羟乙基) 硫胺素焦磷酸酯 (Ia) 脱羧生成 2-(l-羟乙基) 焦磷酸硫胺素 (IIa) 进行的. 本文报道了 Ia 类似物的合成，2-(l-羧基-l-羟乙基)-3,4-二甲基噻唑氯化物 (CHDT 氯化物)，以及 CHDT 脱羧为 2-(l-羟乙基) 的动力学-3,4-二甲基噻唑鎓离子在水、乙醇-水混合物和乙醇中。我们根据所观察到的 CHDT 在水中 67 度脱羧的一级速率常数对 pH 的依赖性得出结论，反应性物质是其中羧基被电离的物质。在极性低于水的溶剂中，这种偶极离子的脱羧速率显着增加；脱羧的半衰期是在 45.6' 的水中为 24.0 小时，在 26.0' 的无水乙醇中为 3.2 分钟。该模型与丙酮酸脱羧酶反应的比较表明，该酶将水中 Ia 的脱羧加速了至少 10 倍。我们提出酶促催化是通过 Ia 的噻
• 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS
  申请人：Castro Pichel Julia

  公开号：US20130203802A1

  公开（公告）日：2013-08-08

  A compound of Formula (I) or a pharmaceutically acceptable salt thereof: Wherein: Het is a 5 to 10-membered heteroaromatic ring; Either X is N and Y is CR 5 ; or X is C and Y is S; Z is selected from N and CH; R 1 is selected from H and C 1-2 alkyl; R 2 is selected from H, C 1-2 alkyl, OH, —CH 2 OH and C 1-2 alkoxy; Each R 3 is independently selected from OH, C 1-3 alkyl, F, Cl, Br, NH 2 , and C 1-3 alkoxy; R 4 is selected from C 1-3 alkyl and haloC 1-3 alkyl; R 5 is selected from H, C 1-3 alkyl and haloC 1-3 alkyl; R 6 and R 7 are either i) each independently selected from H, C 1-3 alkyl and C 1-3 alkoxy; or ii) R 6 and R 7 together with the ring to which they are attached form a 9-membered bicyclic ring; p is 0-3; and R A is selected from H and C 1-3 alkyl, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

  公式（I）的化合物或其药用盐：其中：Het是5至10成员的杂环芳香环；X为N且Y为CR5；或X为C且Y为S；Z从N和CH中选择；R1从H和C1-2烷基中选择；R2从H、C1-2烷基、OH、—CH2OH和C1-2烷氧基中选择；每个R3独立选择自OH、C1-3烷基、F、Cl、Br、NH2和C1-3烷氧基；R4从C1-3烷基和卤代C1-3烷基中选择；R5从H、C1-3烷基和卤代C1-3烷基中选择；R6和R7要么i）各自独立选择自H、C1-3烷基和C1-3烷氧基；要么ii）R6和R7与它们附着的环一起形成9成员双环环；p为0-3；RA从H和C1-3烷基中选择，提供了含有它们的组合物，它们在治疗中的使用，例如在结核病的治疗中，并提供了这类化合物的制备方法。
• [EN] ( PYRAZOL-3-YL) -1, 3, 4-THIADIAZOL-2-AMINE AND ( PYRAZOL-3-YL) -1, 3, 4-THIAZOL-2-AMINE COMPOUNDS<br/>[FR] COMPOSÉS DE (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE ET DE (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE
  申请人：GLAXO GROUP LTD

  公开号：WO2010118852A1

  公开（公告）日：2010-10-21

  wherein: either X is N and Y is CR5 or X is C and Y is S; Z is selected from N and CH; R1 is selected from H and Me; R2 is selected from H, OH, OMe and Me; each R3 is independently selected from C1-3alkyl, F, Cl, Br, CF3 and NH2; R4 is selected from Me, CF3, NO2 and CHF2; R5 is selected from H, Me and CHF2; R6 is selected from H and Me; and p is 0-3, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

  提供其中的化学式：其中，要么X是N且Y是CR5，要么X是C且Y是S；Z从N和CH中选择；R1从H和Me中选择；R2从H、OH、OMe和Me中选择；每个R3独立地从C1-3烷基、F、Cl、Br、CF3和NH2中选择；R4从Me、 、NO2和CHF2中选择；R5从H、Me和 中选择；R6从H和Me中选择；p为0-3。提供了包含它们的组合物，它们在治疗中的应用，例如在结核病的治疗中，以及制备这些化合物的方法。
• 3-amino-pyrazole derivatives useful against tuberculosis
  申请人：Castro Pichel Julia

  公开号：US08779153B2

  公开（公告）日：2014-07-15

  A compound of Formula (I) or a pharmaceutically acceptable salt thereof: Wherein: Het is a 5 to 10-membered heteroaromatic ring; Either X is N and Y is CR5; or X is C and Y is S; Z is selected from N and CH; R1 is selected from H and C1-2alkyl; R2 is selected from H, C1-2alkyl, OH, —CH2OH and C1-2alkoxy; Each R3 is independently selected from OH, C1-3alkyl, F, Cl, Br, NH2, and C1-3alkoxy; R4 is selected from C1-3alkyl and haloC1-3alkyl; R5 is selected from H, C1-3alkyl and haloC1-3alkyl; R6 and R7 are either i) each independently selected from H, C1-3alkyl and C1-3alkoxy; or ii) R6 and R7 together with the ring to which they are attached form a 9-membered bicylic ring; p is 0-3; and RA is selected from H and C1-3alkyl, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

  化合物的式子（I）或其药学上可接受的盐： 其中：Het是5至10个成员的杂环芳香环；X为N且Y为CR5，或者X为C且Y为S；Z从N和CH中选择；R1从H和C1-2烷基中选择；R2从H，C1-2烷基，OH，—CH2OH和C1-2烷氧基中选择；每个R3独立地从OH，C1-3烷基，F，Cl，Br，NH2和C1-3烷氧基中选择；R4从C1-3烷基和haloC1-3烷基中选择；R5从H，C1-3烷基和haloC1-3烷基中选择；R6和R7要么各自独立地从H，C1-3烷基和C1-3烷氧基中选择；要么R6和R7与它们附着的环一起形成一个9成员的双环；p为0-3；RA从H和C1-3烷基中选择，提供了含有它们的组成物，它们在治疗中的使用，例如在结核病的治疗中，以及这种化合物的制备方法。